CALIXAR is proud to announce the approval of the ChikVax project co-submitted with its partners CILOA and INSERM within the framework of the French Inter-Ministry Fund.
The ChikVax project is intended to develop a new generation of vaccines based on the efficiency and synergy of native membrane antigens produced by and with the joint expertise of CALIXAR and CILOA.
The first vaccine prototype to be developed by the 3 partners will be directed against the Chikungunya virus.
